Autonomic nerves in the mammalian choroid plexus and their influence on the formation of cerebrospinal fluid.
The choroid plexuses of all ventricles receive a well-developed adrenergic and cholinergic innervation reaching both the secretory epithelium and the vascular smooth muscle cells. Also peptidergic nerves, containing vasoactive intestinal polypeptide, are present but primarily associated only with the vascular bed. A sympathetic inhibitory effect on the plexus epithelium has been indicated in determinations of carbonic anhydrase activity and by studies of various aspects of active transport in isolated plexus tissue. Pharmacological analysis in vitro has shown the choroidal arteries to possess both vasoconstrictory alpha-adrenergic and vasodilatory beta-adrenergic receptors. Electrical stimulation of the sympathetic nerves, which originate in the superior cervical ganglia, induces as much as 30% reduction in the net rate of cerebrospinal fluid (CSF) production, while sympathectomy results in a pronounced increase, about 30% above control, in the CSF formation. There is strong reason to believe that the choroid plexus is under the influence of a considerable sympathetic inhibitory tone under steady-state conditions. From pharmacological and biochemical experiments it is suggested that the sympathomimetic reduction in the rate of CSF formation is the result of a combined beta-receptor-mediated inhibition of the secretion from the plexus epithelium and a reduced blood flow in the choroid plexus tissue resulting from stimulation of the vascular alpha-receptors. The choroid plexus probably also represents an important inactivation site and gate mechanism for sympathomimetic amines, as evidenced by considerable local activity of catechol-O-methyl transferase and monoamine oxidase, primarily type B. The CSF production rate is also reduced by cholinomimetic agents, suggesting the presence of muscarinic-type cholinergic receptors in the choroid plexus.
D000110:Acetylcholinesterase / Q000378:metabolism; D000320:Adrenergic Fibers / Q000196:embryology / Q000502:physiology / Q000648:ultrastructure; D000818:Animals; D001341:Autonomic Nervous System / Q000378:metabolism* / Q000502:physiology; D001693:Biological Transport, Active / Q000187:drug effects; D002256:Carbonic Anhydrases / Q000378:metabolism; D002415:Cats; D002417:Cattle; D002555:Cerebrospinal Fluid / Q000502:physiology*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002799:Cholinergic Fibers / Q000502:physiology / Q000648:ultrastructure; D002831:Choroid Plexus / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D006224:Cricetinae; D004285:Dogs; D004848:Epithelium / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism; D010215:Papio; D010277:Parasympathomimetics / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology; D013552:Swine; D013566:Sympathomimetics / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
D010277:Parasympathomimetics; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D013566:Sympathomimetics; D012701:Serotonin; D014660:Vasoactive Intestinal Peptide; D008995:Monoamine Oxidase; D000110:Acetylcholinesterase; D002256:Carbonic Anhydrases